Hormonal
Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.
For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.
In Japanese adults with obesity disease, tirzepatide significantly improved HR-QoL over 72 weeks compared with placebo in both physical and psychosocial domains.
Why this rating
Phase 3 randomized, double-blind, placebo-controlled trial (SURMOUNT-J) with a large sample size (n=201) and rigorous statistical analysis.
Source
Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the <scp>SURMOUNT</scp> ‐J Study
Hiroaki Masuzaki et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70850
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →